Basic information
Biomarker: MYBL2
Histology type: endometrial carcinoma
Cohort characteristics
Country: China
Region: Nanchang
Followed up time :
Subgroup 1 name : low expression in TAGA
Subgroup 1 number: 68
Subgroup 2 name: high expression in TCGA
Subgroup 2 number: 72
| Total number | Group I | Group I number | Group II | Group II number | Group III | Group III number | Group IV | Group IV number |
|---|---|---|---|---|---|---|---|---|
| 66 | EC | 33 | adjacent tissues | 33 |
Sample information
Conclusion: The findings in this study provide evidence that MYBL2 can serve as a new candidate prognostic marker and a target for future therapeutic intervention in EC.
Sample method: immunohistochemistry
Expression pattern : expression
Disease information
Statictics: cutoff<60;cutoff>60
Subgroup 1 age: 17;51
Subgroup 2 age: 18;54
Related information
UniProt Link:
Molecular function from UniProt:
Expression figure link: MYBL2 was significantly upregulated with obvious copy number alteration (CNA) in EC. Copy number amplification significantly increased MYBL2 mRNA expression, which led to a poor prognosis and severe pathological types of EC. Additionally, MYBL2 silencing significantly inhibited proliferation and induced apoptosis and G1-phase cell cycle arrest in EC cell lines.
Survival figure legend: The association between MYBL2 overexpression and amplification and clinical data analysis.
Survival curve link: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8054569/figure/fig002/
